Christina Yee MD

Christina Yee, MD



    Contact: 617-355-6117

Medical Services

Departments

  • Allergy Immunology

Programs

  • Allergy Program
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Experience and Education

Publications

Publications powered by Harvard Catalyst Profiles
  1. Yee CS, Rachid R. The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions. Curr Allergy Asthma Rep. 2016 Apr; 16(4):25.
  2. Yee CS, Massaad MJ, Bainter W, Ohsumi TK, Föger N, Chan AC, Akarsu NA, Aytekin C, Ayvaz DÇ, Tezcan I, Sanal Ö, Geha RS, Chou J. Recurrent viral infections associated with a homozygous CORO1A mutation that disrupts oligomerization and cytoskeletal association. J Allergy Clin Immunol. 2016 Mar; 137(3):879-88.e2.
  3. Kumar L, Chou J, Yee CS, Borzutzky A, Vollmann EH, von Andrian UH, Park SY, Hollander G, Manis JP, Poliani PL, Geha RS. Leucine-rich repeat containing 8A (LRRC8A) is essential for T lymphocyte development and function. J Exp Med. 2014 May 5; 211(5):929-42.
  4. Li P, Wang N, Zhou D, Yee CS, Chang CH, Brutkiewicz RR, Blum JS. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J Immunol. 2005 Nov 15; 175(10):6481-8.
  5. Nickerson K, Sisk TJ, Inohara N, Yee CS, Kennell J, Cho MC, Yannie PJ, Nunez G, Chang CH. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J Biol Chem. 2001 Jun 1; 276(22):19089-93.
  6. McFarland HI, Lobito AA, Johnson MM, Palardy GR, Yee CS, Jordan EK, Frank JA, Tresser N, Genain CP, Mueller JP, Matis LA, Lenardo MJ. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J Immunol. 2001 Feb 1; 166(3):2116-21.
  7. Panvichian R, Orth K, Pilat MJ, Day ML, Day KC, Yee C, Kamradt JM, Pienta KJ. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology. 1999 Oct; 54(4):746-52.
  8. Yee CS, Kamradt JM, Nielsen LC, Panvinchian R, Pienta KJ. Carboplatin-induced cell death in model prostate cancer systems. Anticancer Res. 1998 Nov-Dec; 18(6A):4475-82.
  9. Yee CS, Schwab ED, Lehr JE, Quigley M, Pienta KJ. The effect of castanospermine on the metastatic properties of prostate cancer cells. Anticancer Res. 1997 Sep-Oct; 17(5A):3659-63.
  10. Yee CS, Yao Y, Xu Q, McCarthy B, Sun-Lin D, Tone M, Waldmann H, Chang CH. Enhanced production of IL-10 by dendritic cells deficient in CIITA. J Immunol. 2005 Feb 1; 174(3):1222-9.
  11. Show all
  12. Dissanayake S, Perler FB, Xu M, Southworth MW, Yee CK, Wang S, Dreyer G, Watawana L, Kurniawan L, Fuhrman JA, et al. Differential recognition of microfilarial chitinase, a transmission-blocking vaccine candidate antigen, by sera from patients with Brugian and Bancroftian filariasis. Am J Trop Med Hyg. 1995 Sep; 53(3):289-94.
  13. Yee CS, Yao Y, Li P, Klemsz MJ, Blum JS, Chang CH. Cathepsin E: a novel target for regulation by class II transactivator. J Immunol. 2004 May 1; 172(9):5528-34.
  14. O'Connell AE, Lee JP, Yee C, Kesselheim J, Dioun A. Successful desensitization to brentuximab vedotin after anaphylaxis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):e73-5.
  15. Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, Ujhazi B, Chen K, Lee YN, Tirosh I, Dobbs K, Al-Herz W, Cowan MJ, Puck J, Bleesing JJ, Grimley MS, Malech H, De Ravin SS, Gennery AR, Abraham RS, Joshi AY, Boyce TG, Butte MJ, Nadeau KC, Balboni I, Sullivan KE, Akhter J, Adeli M, El-Feky RA, El-Ghoneimy DH, Dbaibo G, Wakim R, Azzari C, Palma P, Cancrini C, Capuder K, Condino-Neto A, Costa-Carvalho BT, Oliveira JB, Roifman C, Buchbinder D, Kumanovics A, Franco JL, Niehues T, Schuetz C, Kuijpers T, Yee C, Chou J, Masaad MJ, Geha R, Uzel G, Gelman R, Holland SM, Recher M, Utz PJ, Browne SK, Notarangelo LD. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015 Nov 2; 125(11):4135-48.
  16. Chou J, Badran YR, Yee CS, Bainter W, Ohsumi TK, Al-Hammadi S, Pai SY, Feske S, Geha RS. A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function. J Allergy Clin Immunol. 2015 Aug; 136(2):479-82.e1.
  17. Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, Ujhazi B, Chen K, Lee YN, Tirosh I, Dobbs K, Al-Herz W, Cowan MJ, Puck J, Bleesing JJ, Grimley MS, Malech H, De Ravin SS, Gennery AR, Abraham RS, Joshi AY, Boyce TG, Butte MJ, Nadeau KC, Balboni I, Sullivan KE, Akhter J, Adeli M, El-Feky RA, El-Ghoneimy DH, Dbaibo G, Wakim R, Azzari C, Palma P, Cancrini C, Capuder K, Condino-Neto A, Costa-Carvalho BT, Oliveira JB, Roifman C, Buchbinder D, Kumanovics A, Franco JL, Niehues T, Schuetz C, Kuijpers T, Yee C, Chou J, Masaad MJ, Geha R, Uzel G, Gelman R, Holland SM, Recher M, Utz PJ, Browne SK, Notarangelo LD. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2016 Nov 1; 126(11):4389.
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close